The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

Merck’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value. Merck ...

Merck's Keytruda scored two important victories in women's cancer, according to presentations Sunday at the ESMO meeting.

Given this outlook, focusing on high-yield dividend stocks and cautious valuation is essential for long-term investment ...

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Merck & Co has agreed to pay rival Bristol-Myers Squibb $625 million, plus royalties, to settle a patent case relating to the companies' rival cancer immunotherapies. Merck’s Keytruda ...

Keytruda (pembrolizumab ... The drug is due to lose patent protection in 2028, however, so MSD (known as Merck & Co in the US) has been working to build its oncology pipeline to absorb the ...

This revenue flow is expected to continue growing with GlobalData predicting that the blockbuster will pull in $33.7bn in 2028, when key Keytruda patents are set to expire. Summit acquired ...

Summit shares hit record high J.P. Morgan analyst Chris Schott said the data does not meaningfully alter their view on Keytruda, which is due to go off-patent in the coming years. Summit did not ...

Keytruda's sales of $7.3 billion jumped 16% year over year. True, Keytruda's patent will expire in 2028. However, the company seems increasingly ready. Merck is working on a subcutaneous version ...

Summit's ivonescimab outperforms Keytruda in lung cancer trial, positioning the company to capture a significant market share ...